SQ 109

Drug Profile

SQ 109

Alternative Names: NSC 722041; SQ109

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; Sequella
  • Developer Infectex; Ludwig-Maximilians-University; Sequella
  • Class Antituberculars; Ethylenediamines; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Tuberculosis
  • Preclinical Mycobacterial infections; Mycoses
  • No development reported Duodenal ulcer; Helicobacter infections
  • Discontinued Crohn's disease

Most Recent Events

  • 24 Mar 2017 Infectex completes a phase IIb/III trial in Tuberculosis in Russia
  • 24 Mar 2017 Efficacy data from a phase IIb/III trial in Tuberculosis released by Sequella
  • 09 Sep 2015 Phase-II/III development is still ongoing for Tuberculosis in South Africa and Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top